ProKidney Corp.
General ticker "PROK" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $624.1M (TTM average)
ProKidney Corp. follows the US Stock Market performance with the rate: 11.1%.
Estimated limits based on current volatility of 4.2%: low 1.77$, high 1.93$
Factors to consider:
- Total employees count: 204 (+25.2%) as of 2024
- Top business risk factors: Dependence on lead product, Regulatory and compliance, Transition to commercialization, Manufacturing risks, Profitability concerns
- Earnings for 3 months up through Q1 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [1.76$, 6.26$]
- 2026-12-31 to 2027-12-31 estimated range: [1.38$, 4.95$]
Financial Metrics affecting the PROK estimates:
- Positive: with PPE of -4.6 at the end of fiscal year the price was neutral
- Negative: negative Operating cash flow
- Negative: negative Operating income
- Positive: Investing cash flow per share per price, % of 32.49 > -0.60
- Positive: Shareholder equity ratio, % of -301.33 <= 19.24
- Positive: Inventory ratio change, % of 0 <= 0
Short-term PROK quotes
Long-term PROK plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.08MM | $0.89MM |
| Operating Expenses | $151.52MM | $183.75MM | $165.90MM |
| Operating Income | $-151.52MM | $-183.68MM | $-165.01MM |
| Non-Operating Income | $22.07MM | $19.74MM | $13.81MM |
| Interest Expense | $0.01MM | $0.01MM | $0.00MM |
| R&D Expense | $106.71MM | $127.67MM | $114.12MM |
| Income(Loss) | $-129.45MM | $-163.93MM | $-151.20MM |
| Taxes | $6.00MM | $-0.60MM | $-0.41MM |
| Net Income(Loss)* | $-35.47MM | $-61.19MM | $-68.99MM |
| Stockholders Equity | $-1,103.40MM | $-994.95MM | $-1,011.20MM |
| Assets | $420.55MM | $441.07MM | $335.57MM |
| Operating Cash Flow | $-90.07MM | $-126.35MM | $-120.12MM |
| Capital expenditure | $34.20MM | $29.51MM | $15.20MM |
| Investing Cash Flow | $-329.98MM | $20.41MM | $103.97MM |
| Financing Cash Flow | $-9.55MM | $144.41MM | $25.57MM |
| Earnings Per Share** | $-0.57 | $-0.62 | $-0.52 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.